Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Schmidt

Showing results (301-310 of 319) with videos related to

Pageof 32
Sort By:
The Journal of Clinical Investigation|August 3, 2007
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoKerstin Schwarzwaelder, Steven J Howe, Manfred Schmidt, et al.
International Journal of Cancer|December 10, 2016
Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferationSebastian M Dieter, Klara M Giessler, Mark Kriegsmann, et al.
ACS Nano|August 25, 2021
Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial CellsCinja Kappel, Christine Seidl, Carolina Medina-Montano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 5, 2011
Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meetingJakub Tolar, Jennifer E Adair, Michael Antoniou, et al.
Science Translational Medicine|March 14, 2014
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicityChristian Jörg Braun, Kaan Boztug, Anna Paruzynski, et al.
Human Gene Therapy. Clinical Development|July 13, 2013
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous diseaseStefan Stein, Simone Scholz, Joachim Schwäble, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2011
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapyAnnette Deichmann, Martijn H Brugman, Cynthia C Bartholomae, et al.
The Journal of Clinical Investigation|August 9, 2008
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsSteven J Howe, Marc R Mansour, Kerstin Schwarzwaelder, et al.
Nature Medicine|December 8, 2009
Comprehensive genomic access to vector integration in clinical gene therapyRichard Gabriel, Ralph Eckenberg, Anna Paruzynski, et al.
The Journal of Clinical Investigation|August 3, 2007
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyAnnette Deichmann, Salima Hacein-Bey-Abina, Manfred Schmidt, et al.
Pageof 32

Showing results (301-310 of 319) with videos related to

Sort By:
Pageof 32
The Journal of Clinical Investigation|August 3, 2007
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoKerstin Schwarzwaelder, Steven J Howe, Manfred Schmidt, et al.
International Journal of Cancer|December 10, 2016
Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferationSebastian M Dieter, Klara M Giessler, Mark Kriegsmann, et al.
ACS Nano|August 25, 2021
Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial CellsCinja Kappel, Christine Seidl, Carolina Medina-Montano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 5, 2011
Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meetingJakub Tolar, Jennifer E Adair, Michael Antoniou, et al.
Science Translational Medicine|March 14, 2014
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicityChristian Jörg Braun, Kaan Boztug, Anna Paruzynski, et al.
Human Gene Therapy. Clinical Development|July 13, 2013
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous diseaseStefan Stein, Simone Scholz, Joachim Schwäble, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2011
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapyAnnette Deichmann, Martijn H Brugman, Cynthia C Bartholomae, et al.
The Journal of Clinical Investigation|August 9, 2008
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsSteven J Howe, Marc R Mansour, Kerstin Schwarzwaelder, et al.
Nature Medicine|December 8, 2009
Comprehensive genomic access to vector integration in clinical gene therapyRichard Gabriel, Ralph Eckenberg, Anna Paruzynski, et al.
The Journal of Clinical Investigation|August 3, 2007
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyAnnette Deichmann, Salima Hacein-Bey-Abina, Manfred Schmidt, et al.
Pageof 32